Company News 

GlaxoSmithKline's income status under threat

GlaxoSmithKline's income status under threat

News that US pharmaceutical giant Pfizer is planning to sell its consumer healthcare division and that GlaxoSmithKline (GSK) may decide to buy it, overshadowed the latter’s third-quarter results. Investors have previously criticised the UK group for prioritising toothpaste over potentially life-saving medicine and seemed unimpressed when chief executive Emma Walmsley confirmed her interest in building up its consumer business. The shares dropped by as much as 6 per cent on the day of the announcement, despite it posting consensus-beating pre-tax profits during the three months to September 2017.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now